Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#2
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#3
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#4
JOURNAL ARTICLE
Stephanie Chang
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#5
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#6
JOURNAL ARTICLE
Mark Loeb, Amy Bartholomew, Madiha Hashmi, Wadea Tarhuni, Mohamed Hassany, Ilan Youngster, Ranjani Somayaji, Oscar Larios, Joseph Kim, Bayan Missaghi, Joseph V Vayalumkal, Dominik Mertz, Zain Chagla, Maureen Cividino, Karim Ali, Sarah Mansour, Lana A Castellucci, Charles Frenette, Leighanne Parkes, Mark Downing, Matthew Muller, Verne Glavin, Jennifer Newton, Ravi Hookoom, Jerome A Leis, James Kinross, Stephanie Smith, Sayem Borhan, Pardeep Singh, Eleanor Pullenayegum, John Conly
BACKGROUND: It is uncertain if medical masks offer similar protection against COVID-19 compared with N95 respirators. OBJECTIVE: To determine whether medical masks are noninferior to N95 respirators to prevent COVID-19 in health care workers providing routine care. DESIGN: Multicenter, randomized, noninferiority trial. (ClinicalTrials.gov: NCT04296643). SETTING: 29 health care facilities in Canada, Israel, Pakistan, and Egypt from 4 May 2020 to 29 March 2022...
November 29, 2022: Annals of Internal Medicine
#7
JOURNAL ARTICLE
Gail E Potter, Tyler Bonnett, Kevin Rubenstein, David A Lindholm, Rekha R Rapaka, Sarah B Doernberg, David C Lye, Richard A Mularski, Noreen A Hynes, Susan Kline, Catharine I Paules, Cameron R Wolfe, Maria G Frank, Nadine G Rouphael, Gregory A Deye, Daniel A Sweeney, Rhonda E Colombo, Richard T Davey, Aneesh K Mehta, Jennifer A Whitaker, Jose G Castro, Alpesh N Amin, Christopher J Colombo, Corri B Levine, Mamta K Jain, Ryan C Maves, Vincent C Marconi, Robert Grossberg, Sameh Hozayen, Timothy H Burgess, Robert L Atmar, Anuradha Ganesan, Carlos A Gomez, Constance A Benson, Diego Lopez de Castilla, Neera Ahuja, Sarah L George, Seema U Nayak, Stuart H Cohen, Tahaniyat Lalani, William R Short, Nathaniel Erdmann, Kay M Tomashek, Pablo Tebas
BACKGROUND: The COVID-19 standard of care (SOC) evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. OBJECTIVE: To evaluate whether recovery and mortality improved as SOC evolved, using data from ACTT (Adaptive COVID-19 Treatment Trial). DESIGN: ACTT is a series of phase 3, randomized, double-blind, placebo-controlled trials that evaluated COVID-19 therapeutics from February 2020 through May 2021. ACTT-1 compared remdesivir plus SOC to placebo plus SOC, and in ACTT-2 and ACTT-3, remdesivir plus SOC was the control group...
November 29, 2022: Annals of Internal Medicine
#8
JOURNAL ARTICLE
Mark É Czeisler, Charles A Czeisler
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#9
JOURNAL ARTICLE
Amir Qaseem, Jennifer Yost, Matthew C Miller, Rebecca Andrews, Janet A Jokela, Mary Ann Forciea, George M Abraham, Linda L Humphrey
Description: Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data emerge on SARS-CoV-2 variants and the availability of newer treatments. The Scientific Medical Policy Committee (SMPC) of the American College of Physicians (ACP) developed these living, rapid practice points to summarize the best available evidence on the treatment of adults with confirmed COVID-19 in an outpatient setting. These practice points do not evaluate COVID-19 treatments in the inpatient setting or adjunctive COVID-19 treatments in the outpatient setting...
November 29, 2022: Annals of Internal Medicine
#10
EDITORIAL
Robert A Kleinman, Thomas D Brothers, Nathaniel P Morris
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#11
REVIEW
Haley K Holmer, Katherine Mackey, Celia V Fiordalisi, Mark Helfand
BACKGROUND: The durability of the antibody response after SARS-CoV-2 infection and the role of antibodies in protection against reinfection are unclear. PURPOSE: To synthesize evidence on the SARS-CoV-2 antibody response and reinfection risk with a focus on gaps identified in our prior reports. DATA SOURCES: MEDLINE (Ovid), EMBASE, CINAHL, World Health Organization Research Database, and reference lists from 16 December 2021 through 8 July 2022, with surveillance through 22 August 2022...
November 29, 2022: Annals of Internal Medicine
#12
JOURNAL ARTICLE
Todd C Lee, David R Boulware
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#13
JOURNAL ARTICLE
Roger Chou
No abstract text is available yet for this article.
November 29, 2022: Annals of Internal Medicine
#14
REVIEW
Isolde Sommer, Andreea Dobrescu, Dominic Ledinger, Isabel Moser, Kylie Thaler, Emma Persad, Martin Fangmeyer, Robert Emprechtinger, Irma Klerings, Gerald Gartlehner
BACKGROUND: Clinicians and patients want to know the benefits and harms of outpatient treatment options for SARS-CoV-2 infection. PURPOSE: To assess the benefits and harms of 12 different COVID-19 treatments in the outpatient setting. DATA SOURCES: Epistemonikos COVID-19 L·OVE Platform, searched on 4 April 2022. STUDY SELECTION: Two reviewers independently screened abstracts and full texts against a priori-defined criteria...
November 29, 2022: Annals of Internal Medicine
#15
JOURNAL ARTICLE
Fareed A Awan, Andrew B Becker, Yuetong Wang, Jonathan Kimmelman
BACKGROUND: Many participants in clinical trials supporting U.S. Food and Drug Administration (FDA) drug approvals are recruited from outside the United States, including from low- and middle-income countries (LMICs). Where participants are recruited for pivotal trials has implications for ethical research conduct and generalizability. OBJECTIVE: To describe LMIC recruitment for pivotal trials of newly approved drugs for cancer, neurologic disease, and cardiovascular disease...
November 22, 2022: Annals of Internal Medicine
#16
JOURNAL ARTICLE
Newton E Kendig, Renee Butkus, Suja Mathew, David Hilden
The American College of Physicians (ACP) has a long-standing commitment to improving the health of all Americans and opposes any form of discrimination in the delivery of health care services. ACP is committed to working toward fully understanding and supporting the unique needs of the incarcerated population and eliminating health disparities for these persons. In this position paper, ACP offers recommendations to policymakers and administrators to improve the health and well-being of persons incarcerated in adult correctional facilities...
November 22, 2022: Annals of Internal Medicine
#17
EDITORIAL
George R Thompson, Tom M Chiller
No abstract text is available yet for this article.
November 22, 2022: Annals of Internal Medicine
#18
JOURNAL ARTICLE
Mónica Lalanda
No abstract text is available yet for this article.
November 22, 2022: Annals of Internal Medicine
#19
(no author information available yet)
No abstract text is available yet for this article.
November 15, 2022: Annals of Internal Medicine
#20
JOURNAL ARTICLE
Erin K McCreary, Lara Lemon, Christina Megli, Amber Oakes, Christopher W Seymour
BACKGROUND: Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19. However, no studies have evaluated adverse events and effectiveness of mAbs in pregnant persons compared with no mAb treatment. OBJECTIVE: To determine the frequency of drug-related adverse events and obstetric-associated safety outcomes after treatment with mAb compared with no mAb treatment of pregnant persons, and the association between mAb treatment and a composite of 28-day COVID-19-related hospital admission or emergency department (ED) visit, COVID-19-associated delivery, or mortality...
November 15, 2022: Annals of Internal Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
